# Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer

> **NCT05545436** · PHASE2 · UNKNOWN · sponsor: **Third Affiliated Hospital, Sun Yat-Sen University** · enrollment: 34 (estimated)

## Conditions studied

- Locally Advanced Gastric Cancer

## Interventions

- **DRUG:** Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )

## Key facts

- **NCT ID:** NCT05545436
- **Lead sponsor:** Third Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-20
- **Primary completion:** 2022-12
- **Final completion:** 2023-06
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2022-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05545436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05545436, "Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05545436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*